Overview

Impact of Oral Versatile Antioxidants on Glaucoma Progression

Status:
Completed

Trial end date:
2012-02-01

Target enrollment:
0

Participant gender:
All

Summary

Background: The significance of retinal ganglion cell protection in the glaucoma led the view that, glaucomatous optical neuropathy can also be considered as a pathology of central nervous system. It is known that α-tocopherol and Gingko Biloba have specific neuroprotective and vasoregulatory activities, in addition to antioxidant effects. In this study, the investigators compared early neuroprotective effects of α-tocopherol and GB with each other as well as control and a strong antioxidant formulation in patients with glaucoma. Methods: In this non-randomized control trial, 120 eyes of 60 patients with glaucoma were enrolled into the study and divided into 4 groups, each consisting of 30 eyes. Unlike the controls, patients in the 3 antioxidant groups received α-tocopherol, Gingko Biloba and a strong antioxidant formula for 3 months. Central vision field and MD, PSD and OCT as well as thickness of retinal nerve fiber layer, ganglion cell counts and c/d ratios were recorded. The data were compared statistically.

Phase:

Phase 3

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Bagcilar Training and Research Hospital

Treatments:

alpha-Tocopherol
Antioxidants
Tocopherols
Tocotrienols
Vitamin E

Criteria

Inclusion Criteria:

- Patients who received follow-up in our glaucoma polyclinics

Exclusion Criteria:

- Known ocular or systemic concomitant disorders

- Previous glaucoma surgeries

- Antioxidant usage